[1]张照华,杨玲玲,张盼盼,等.贝伐单抗对视网膜色素上皮细胞抗氧化功能的影响[J].眼科新进展,2017,37(4):305-309.[doi:10.13389/j.cnki.rao.2017.0077]
　ZHANG Zhao-Hua,YANG Ling-Ling,ZHANG Pan-Pan,et al.Effects of bevacizumab on antioxidative function in human retinal pigment epithelial cells[J].Recent Advances in Ophthalmology,2017,37(4):305-309.[doi:10.13389/j.cnki.rao.2017.0077]
点击复制

贝伐单抗对视网膜色素上皮细胞抗氧化功能的影响/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年4期
页码:
305-309
栏目:
实验研究
出版日期:
2017-04-05

文章信息/Info

Title:
Effects of bevacizumab on antioxidative function in human retinal pigment epithelial cells
作者:
张照华; 杨玲玲; 张盼盼; 董琪; 徐海峰
266071　山东省青岛市，青岛大学医学院、山东省眼科研究所 青岛眼科医院（张照华）；266071山东省青岛市，山东省眼科研究所 青岛眼科医院（张盼盼，董琪，徐海峰）；266071　山东省青岛市，山东省眼科研究所 山东省眼科学重点实验室（杨玲玲）
Author(s):
ZHANG Zhao-Hua; YANG Ling-Ling; ZHANG Pan-Pan; DONG Qi; XU Hai-Feng
Medical College of Qingdao University，Qingdao Eye Hospital，Shandong Eye Institute(ZHANG Zhao-Hua)，Qingdao 266071，Shandong Province，China；Qingdao Eye Hospital，Shandong Eye Institute(ZHANG Pan-Pan，DONG Qi，XU Hai-Feng)，Qingdao 266071，Shandong Province，China；Shandong Provincial Key Laboratory of Ophthalmology，Shandong Eye Institute(YANG Ling-Ling)，Qingdao 266071，Shandong Province，China
关键词:
年龄相关性黄斑变性; 贝伐单抗; 活性氧; 人视网膜色素上皮细胞
Keywords:
age-related macular degeneration; bevacizumab; reactive oxygen species; human retinal pigment epithelial cells
分类号:
R774
DOI:
10.13389/j.cnki.rao.2017.0077
文献标志码:
A
摘要:
目的　观察贝伐单抗对人视网膜色素上皮（retinal pigment epithelium，RPE）细胞抗氧化功能的影响，以探讨抗新生血管内皮生长因子（vascular endothelial growth factor，VEGF）制剂治疗年龄相关性黄斑变性后黄斑部萎缩的可能机制。方法　用含终浓度0.25 g·L-1贝伐单抗的DMED/F12培养液培养人RPE细胞系ARPE-19细胞，根据处理时间的不同分为0 h组（对照组）、12 h组、24 h组、48 h组、72 h组共5组，加入H2O2诱导氧化应激反应。用CCK-8法检测细胞活性，MitoSox Red荧光染色检测细胞内线粒体活性氧（reactive oxygen species，ROS）产生水平，JC-1荧光染色检测细胞线粒体膜电位的变化；分别用逆转录聚合酶链反应（RT-PCR）及免疫蛋白印迹法（Western blot）检测各组促氧化因子NADPH氧化酶4（NADPH oxidase 4，NOX4）和抗氧化因子血红素氧合酶-1（heme oxygenase-1，HO-1） mRNA和蛋白的表达水平。结果　CCK-8检测结果显示：上述处理对细胞活性无显著影响，0 h组、12 h组、24 h组、48 h组和72 h组细胞活性分别为（100.2±3.3）%、（99.2±2.7）%、(102.5±6.4）%、(103.9±3.7)%和（103.6±3.3）%，差异无统计学意义（P>0.05）；与对照组相比，12 h、24 h、48 h、72 h组细胞内ROS水平上升，差异有统计学意义（P<0.05）；线粒体膜电位在12 h、24 h、48 h、72 h组均较对照组降低，差异有统计学意义（P<0.01），48 h达最低，72 h时显著提高，但仍低于对照组。RT-PCR和Western blot检测结果显示：与对照组比较，NOX4 mRNA和蛋白的表达在12 h、24 h、48 h和72 h组均上升，而且在24 h表达最高，之后明显下降，但仍高于对照组，差异有统计学意义（P<0.01）。与对照组比较，HO-1 mRNA的表达在24 h、48 h和72 h组均下降，而HO-1蛋白的表达在48 h和72 h组下降，差异有统计学意义（P<0.05）。结论　临床浓度的贝伐单抗可以降低RPE的抗氧化功能，可能是长期抗VEGF治疗后黄斑部进行性萎缩的原因之一。
Abstract:
Objective　To investigate the effects of bevacizumab on the antioxidative function of human retinal pigment epithelium (RPE),in order to explore the possible mechanism of macular atrophy induced by the application of anti-vascular epithelial growth factor (VEGF) agents in age-related macular degeneration.Methods　Human RPE cells were incubated in DMEM/F12 medium containing 0.25 g·L-1 bevacizumab and divided into 5 groups according to incubation period:0 hour(control)，12 hours，24 hours，48 hours and 72 hours,and then the oxidative stress was induced by adding H2O2.Cell viability was measured by the CCK8 assay.MitoSox Red was used to determine mitochondrial reactive oxygen species (mtROS) production.Mitochondrial membrane potential was measured using the JC-1 assay.The expression levels of NOX4 and HO-1 were detected by RT-PCR and Western blot,respectively.Results　CCK8 assay determination showed that the above treatment had no significant effect on cell viability,the cell viability of 0 hours,12 hours,24 hours,48 hours and 72 hours were（100.2±3.3）%,（99.2±2.7）%，(102.5±6.4）%,(103.9±3.7)%,（103.6±3.3）%,the difference was not statistically significant (P>0.05).Compared with the control group,the levels of mtROS increased at 12 hours,24 hours,48 hours and 72 hours,the difference was statistically significant (P<0.05).Mitochondrial membrane potential at 12 hours,24 hours,48 hours,72 hours were lower than the control group,the difference was significant,48 hours reached the lowest,72 hours significantly increased,but still lower than the control group.RT-PCR and western blot results demonstrated that the expression of NOX4 mRNA and protein increased at 12 hours,24 hours,48 hours and 72 hours,and reached the highest at 24 hours,then decreased significantly,but still higher than the control group,the difference was statistically significant (P<0.01).Compared with the control group,the expression of HO-1 mRNA decreased at 24 hours,48 hours and 72 hours,while the expression of HO-1 protein decreased at 48 hours and 72 hours,the difference was statistically significant (P<0.05).Conclusion　The clinical concentration of bevacizumab can reduce the anti-oxidative function of RPE cells,which may be one of the causes of progressive macular atrophy after long-term anti-VEGF therapy.

参考文献/References:

［1］　JAGER RD，MIELER WF，MILLER JW.Age-related macular degeneration［J］.N Engl J Med，2008，358(24)：2606-2617.
［2］　CONGDON NG，FRIEDMAN DS，LIETMAN T.Important causes of visual impairment in the world today［J］.JAMA，2003，290(15)：2057-2060.
［3］　VINGERLING JR，DIELEMANS I，HOFMAN A，GROBBEE DE，HIJMERING M，KRAMER CF，et al.The prevalence of age-related maculopathy in the Rotterdam Study［J］.Ophthalmology，1995，102(2)：205-210.
［4］　VELEZ-MONTOYA R，OLIVER SC，OLSCON JL，FINE SL，MANDAVA N，QUIROZ-MERCADO H.Current knowledge and trends in age-related macular degeneration：today’s and future treatments［J］.Retina，2013，33(8)：1487-1502.
［5］　CATT RESEARCH GROUP.Ranibizumab and bevacizumab for neovascular age-related macular degeneration［J］.N Engl J Med，2011，364(19)：1897-1908.
［6］　YOUNG M，CHUI L，FALLAH N，OR C，MERKUR AB，KIRKER AW，et al.Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration［J］.Retina，2014，34(7)：1308-1315.
［7］　LOIS N，MCBAIN V，ABDELKADER E，SCOTT NW，KUMARI R.Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy［J］.Retina，2013，33(1)：13-22.
［8］　GRUNWALD JE，DANIEL E，HUANG J，YING GS，MAGUIRE MG，TOTH CA，et al.Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2014，121(1)：150-161.
［9］　ROSENFELD PJ，BROWN DM，HEIER JS，BOYER DS，KAISER PK，CHUNG CY，et al.Ranibizumab for neovascular age-related macular degeneration［J］.N Engl J Med，2006，355(14)：1419-1431.
［10］　MARTIN DF，MAGUIRE MG，FINE SL，YING GS，JAFFE GJ，GRUNWALD JE，et al.Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration：two-year results［J］.Ophthalmology，2012，119(7)：1388-1398.
［11］　ROFAGHA S，BHISITKUL RB，BOYER DS，SADDA SR，ZHANG K；SEVEN-UP STUDY GROUP.Seven-year outcomes in ranibizumab-treated patients in ANCHOR，MARINA，and HORIZON：a multicenter cohort study (SEVEN-UP)［J］.Ophthalmology，2013，120(11)：2292-2299.
［12］　PEDEN MC，SUNER IJ，HAMMER ME，GRIZZARD WS.Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration［J］.Ophthalmology，2015，122(4)：803-808.
［13］　BHISITKUL RB，MENDES TS，ROFAGHA S，ENANORIA W，BOYER DS，SADDA SR，et al.Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR，MARINA，and HORIZON studies：the SEVEN-UP study［J］.Am J Ophthalmol，2015，159(5)：915-924.
［14］　KREGEL KC，ZHANG HJ.An integrated view of oxidative stress in aging：basic mechanisms，functional effects，and pathological considerations［J］.Am J Physiol Regul Integr Comp Physiol，2007，292(1)：R18-36.
［15］　TRACHOOTHAM D，LU W，OGASAWARA MA，VALLE NRD，HUANG P.Redox regulation of cell survival［J］.Antioxid Redox Signal，2008，10(8)：1343-1374.
［16］　MALIK D，TAREK M，Del CARPIO JC，RAMIREZ C，BOYER D，KENNEY MC，et al.Safety profiles of anti-VEGF drugs：bevacizumab，ranibizumab，aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture［J］.Br J Ophthalmol，2014，98(Suppl 1)：11-16.
［17］　BEDARD K，KRAUSE KH.The NOX family of ROS-generating NADPH oxidases：physiology and pathophysiology［J］.Physiol Rev，2007，87(1)：245-313.
［18］　QIU Y，TAO L，LEI C，WANDG J，YANG P，LI Q，et al.Downregulating p22phox ameliorates inflammatory response in Angiotensin Ⅱ-induced oxidative stress by regulating MAPK and NF-κB pathways in ARPE-19 cells［J］.Sci Rep，2015，5(2)：143-162.
［19］　ZHOU W，QUAN JH，LEE YH，SHIN DW，CHA GH.Toxoplasma gondii proliferation require down-regulation of host Nox4 expression via activation of PI3 kinase/Akt signaling pathway［J］.PLoS One，2013，8(6)：e66306.
［20］　CRESTANI B，BESNARD V，BOCZKOWSKI J.Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis［J］.Int J Biochem Cell Biol，2011，43(8)：1086-1089.
［21］　LIU RM，DESAI LP.Reciprocal regulation of TGF-β and reactive oxygen species：a perverse cycle for fibrosis［J］.Redox Biol，2015，6：565-577.
［22］　BAUER KM，WATTS TN，BUECHLER S，HUMMON AB.Proteomic and functional investigation of the colon cancer relapse-associated genes NOX4 and ITGA3［J］.J Proteome Res，2014，13(11)：4910-4918.
［23］　伊文霞，韩颖，赵阳，张静，秦炯.内源性一氧化碳对反复热性惊厥脑损伤大鼠内质网应激PERK信号通路的调控作用［J］.中华实用儿科临床杂志，2013，28(19)：1502-1505.
YI WX，HAN Y，ZHAO Y，ZHANG J，QIN J.Regulating effect of endogenous carbon monoxide on brain damage induced by recurrent febrile seizures through GRP78-PERK-eIF2α-CHOP signal pathway［J］.Chin J Appl Clin Pediatr，2013，28(19)：1502-1505.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[3]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[4]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[5]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[6]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[9]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]张盼盼,董琪,华英彬,等.贝伐单抗对人视网膜色素上皮细胞形态、凋亡率及凋亡相关因子表达的影响[J].眼科新进展,2018,38(4):314.[doi:10.13389/j.cnki.rao.2018.0074]
　ZHANG Pan-Pan,DONG Qi,HUA Ying-Bin,et al.Effects of bevacizumab on morphology and apoptosis of human retinal pigment epithelial cells as well as the expression of apoptosis-related factors[J].Recent Advances in Ophthalmology,2018,38(4):314.[doi:10.13389/j.cnki.rao.2018.0074]

备注/Memo

备注/Memo:
国家自然科学基金面上项目（编号：81670828）；山东省自然科学基金资助（编号：ZR2014HM029）
更新日期/Last Update: 2017-04-26